Co-Encapsulation of Paclitaxel and Doxorubicin in Liposomes Layer by Layer

Author:

Mota Díaz Isaac Izcoatl1ORCID,Douda Janna23ORCID,García López Patricia4ORCID,Cabrera Becerra Sandra Edith5,Gómez Álvarez Miguel Ángel6,Jiménez Rodríguez Rebeca2ORCID,Jurado León Rafael4,López Sánchez Pedro5

Affiliation:

1. Unidad Profesional Interdisciplinaria de Ingeniería Campus Palenque, Instituto Politécnico Nacional, Carretera Palenque-Pakal-Na S/N, Palenque 29960, Chis, Mexico

2. Unidad Profesional Interdisciplinaria en Ingeniería y Tecnologías Avanzadas, Instituto Politécnico Nacional, Othón Mendizábal S/N, La Escalera 07320, CDMX, Mexico

3. Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Zacatenco 07738, CDMX, Mexico

4. Instituto Nacional de Cancerología (INCan), Tlalpan 4080, CDMX, Mexico

5. Escuela Superior de Medicina, Instituto Politécnico Nacional, Salvador Díaz Mirón esq. Plan de San Luis S/N, Miguel Hidalgo, Casco de Santo Tomas 11340, CDMX, Mexico

6. Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Libramiento Norponiente No. 2000 Real de Juriquilla, Santiago de Querétaro 76230, QRO, Mexico

Abstract

The synergistic effect of antineoplastic drug co-encapsulation systems has made them highly regarded due to their improved pharmacological efficacy. Biopolymer-coated liposomes were evaluated for paclitaxel and doxorubicin co-encapsulation in MCF-7 and MDA-MB-231 breast cancer cell lines. These nanosystems are characterized by dynamic light scattering, transmission electron microscopy, and UV–VIS spectroscopy. The conventional and hybrid liposomal systems presented sizes of 150 to 230 nm and %EE greater than 80% for the encapsulated active ingredients. These drug-laden liposomal systems significantly decreased cell viability in both breast cancer cell lines compared with liposome-free drugs. The delivery of antineoplastic drugs in breast cancer therapy could potentially benefit from new hybrids for drug co-encapsulation.

Funder

SIP-IPN

Consejo Nacional de Humanidades, Ciencias y Tecnologías: PhD scholarship

Publisher

MDPI AG

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3